Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: Structure-activity relationship study directed toward the improvement of metabolic stability

Journal of Medicinal Chemistry

Volumn 39, Issue 20, 1996, Pages 3951-3970

  Delorme, Daniel ^a,b   Ducharme, Yves ^a   Brideau, Christine ^a   Chan, Chi Chung ^a   Chauret, Nathalie ^a   Desmarais, Sylvie ^a   Dubé, Daniel ^a   Falgueyret, Jean Pierre ^a   Fortin, Réjean ^a   Guay, Jocelyne ^a   Hamel, Pierre ^a   Jones, Tom R ^a   Lépine, Carole ^a   Li, Chun ^a   McAuliffe, Malia ^a   McFarlane, Cyril S ^a   Nicoll Griffith, Deborah A ^a   Riendeau, Denis ^a   Yergey, James A ^a   Girard, Yves ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b Astra Pain Research Unit   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROPEROXY 6,8,11,14 ICOSATETRAENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE B4; TETRAHYDROFURAN;

AEROBIC METABOLISM; ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; ASTHMA; BRONCHOSPASM; ENZYME MECHANISM; NONHUMAN; RHEUMATOID ARTHRITIS; SQUIRREL MONKEY;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; BENZOFURANS; BRONCHOCONSTRICTION; DRUG STABILITY; HUMANS; LEUKOTRIENE B4; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NAPHTHALENES; NEUTROPHILS; NITRILES; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; SAIMIRI; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10144260637     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960301c     Document Type: Article

References (35)

1. (a) For reviews on the 5-LO enzyme, see: Ford-Hutchinson, A. W.; Gresser, M.; Young, R. N. 5-Lipoxygenase. Annu. Rev. Biochem. 1994, 63, 383-417. Musser, J. H.; Kraft, A. F. 5-Lipoxygenase: Properties, Pharmacology, and the Quinolinyl (bridged) aryl Class of Inhibitors. J. Med. Chem. 1992, 35, 2501-2524. (b) For a review on the leukotrienes, see: Rokach, J., Ed. Leukotrienes and Lipoxygenases. Chemical, Biological and Clinical Aspects; Elsevier: Amsterdam, 1989.
2. (a) For reviews on the 5-LO enzyme, see: Ford-Hutchinson, A. W.; Gresser, M.; Young, R. N. 5-Lipoxygenase. Annu. Rev. Biochem. 1994, 63, 383-417. Musser, J. H.; Kraft, A. F. 5-Lipoxygenase: Properties, Pharmacology, and the Quinolinyl (bridged) aryl Class of Inhibitors. J. Med. Chem. 1992, 35, 2501-2524. (b) For a review on the leukotrienes, see: Rokach, J., Ed. Leukotrienes and Lipoxygenases. Chemical, Biological and Clinical Aspects; Elsevier: Amsterdam, 1989.
3. (a) For reviews on the 5-LO enzyme, see: Ford-Hutchinson, A. W.; Gresser, M.; Young, R. N. 5-Lipoxygenase. Annu. Rev. Biochem. 1994, 63, 383-417. Musser, J. H.; Kraft, A. F. 5-Lipoxygenase: Properties, Pharmacology, and the Quinolinyl (bridged) aryl Class of Inhibitors. J. Med. Chem. 1992, 35, 2501-2524. (b) For a review on the leukotrienes, see: Rokach, J., Ed. Leukotrienes and Lipoxygenases. Chemical, Biological and Clinical Aspects; Elsevier: Amsterdam, 1989.
4. 4 in Inflammation. Crit. Rev. Immunol. 1990, 10, 1-12.
5. Ford-Hutchinson, A. W. Leukotrienes: Their Formation and Role as Inflammatory Mediators. Fed. Proc. 1985, 44, 25-29.
6. It has recently been established that 5-LO inhibitors are clinically active in treating asthma: (a) Israel, E. Moderating the Inflammation of Asthma: Inhibiting the Production or Action of Products of the 5-Lipoxygenase Pathway. Ann. Allergy 1994, 72, 279-284. (b) Israel, E.; Fischer, A. R.; Rosenberg, M. A.; Lilly, C. M.; Callery, J. C.; Shapiro, J.; Cohn, J.; Rubin, P.; Drazen, J. M. The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin. Am. Rev. Respir. Dis. 1993, 148, 1447-1451. (c) Israel, E.; Dermarkarian, R.; Rosenberg, M.; Sperling, R.; Taylor, G.; Rubin, P.; Drazen, J. F. The Effects of a 5-Lipoxygenase Inhibitor on Asthma Induced by Cold, Dry Air. N. Engl. J. Med. 1990, 323, 1740-1744. (d) Bel, E. H.; Tanaka, W.; Spector, R.; Friedman, B.; von de Veer, H.; Diijkman, J. H.; Sterk, P. J. MK-886, an Effective Oral Leukotriene Biosynthesis Inhibitor on Antigen-Induced Early and Late Asthmatic Reactions in Man. Am. Rev. Respir. Dis. 1990, 141, A31.
7. It has recently been established that 5-LO inhibitors are clinically active in treating asthma: (a) Israel, E. Moderating the Inflammation of Asthma: Inhibiting the Production or Action of Products of the 5-Lipoxygenase Pathway. Ann. Allergy 1994, 72, 279-284. (b) Israel, E.; Fischer, A. R.; Rosenberg, M. A.; Lilly, C. M.; Callery, J. C.; Shapiro, J.; Cohn, J.; Rubin, P.; Drazen, J. M. The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin. Am. Rev. Respir. Dis. 1993, 148, 1447-1451. (c) Israel, E.; Dermarkarian, R.; Rosenberg, M.; Sperling, R.; Taylor, G.; Rubin, P.; Drazen, J. F. The Effects of a 5-Lipoxygenase Inhibitor on Asthma Induced by Cold, Dry Air. N. Engl. J. Med. 1990, 323, 1740-1744. (d) Bel, E. H.; Tanaka, W.; Spector, R.; Friedman, B.; von de Veer, H.; Diijkman, J. H.; Sterk, P. J. MK-886, an Effective Oral Leukotriene Biosynthesis Inhibitor on Antigen-Induced Early and Late Asthmatic Reactions in Man. Am. Rev. Respir. Dis. 1990, 141, A31.
8. It has recently been established that 5-LO inhibitors are clinically active in treating asthma: (a) Israel, E. Moderating the Inflammation of Asthma: Inhibiting the Production or Action of Products of the 5-Lipoxygenase Pathway. Ann. Allergy 1994, 72, 279-284. (b) Israel, E.; Fischer, A. R.; Rosenberg, M. A.; Lilly, C. M.; Callery, J. C.; Shapiro, J.; Cohn, J.; Rubin, P.; Drazen, J. M. The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin. Am. Rev. Respir. Dis. 1993, 148, 1447-1451. (c) Israel, E.; Dermarkarian, R.; Rosenberg, M.; Sperling, R.; Taylor, G.; Rubin, P.; Drazen, J. F. The Effects of a 5-Lipoxygenase Inhibitor on Asthma Induced by Cold, Dry Air. N. Engl. J. Med. 1990, 323, 1740-1744. (d) Bel, E. H.; Tanaka, W.; Spector, R.; Friedman, B.; von de Veer, H.; Diijkman, J. H.; Sterk, P. J. MK-886, an Effective Oral Leukotriene Biosynthesis Inhibitor on Antigen-Induced Early and Late Asthmatic Reactions in Man. Am. Rev. Respir. Dis. 1990, 141, A31.
9. It has recently been established that 5-LO inhibitors are clinically active in treating asthma: (a) Israel, E. Moderating the Inflammation of Asthma: Inhibiting the Production or Action of Products of the 5-Lipoxygenase Pathway. Ann. Allergy 1994, 72, 279-284. (b) Israel, E.; Fischer, A. R.; Rosenberg, M. A.; Lilly, C. M.; Callery, J. C.; Shapiro, J.; Cohn, J.; Rubin, P.; Drazen, J. M. The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin. Am. Rev. Respir. Dis. 1993, 148, 1447-1451. (c) Israel, E.; Dermarkarian, R.; Rosenberg, M.; Sperling, R.; Taylor, G.; Rubin, P.; Drazen, J. F. The Effects of a 5-Lipoxygenase Inhibitor on Asthma Induced by Cold, Dry Air. N. Engl. J. Med. 1990, 323, 1740-1744. (d) Bel, E. H.; Tanaka, W.; Spector, R.; Friedman, B.; von de Veer, H.; Diijkman, J. H.; Sterk, P. J. MK-886, an Effective Oral Leukotriene Biosynthesis Inhibitor on Antigen-Induced Early and Late Asthmatic Reactions in Man. Am. Rev. Respir. Dis. 1990, 141, A31.
10. (a) Ducharme, Y.; Brideau, C.; Dubé, D.; Chan, C.-C.; Falgueyret, J.-P.; Gillard, J. W.; Guay, J.; Hutchinson, J. H.; McFarlane, C. S.; Riendeau, D.; Scheigetz, J.; Girard, Y. Naphthalenic Lignan Lactones as Selective, Non-redox 5-Lipoxygenase Inhibitors. Synthesis and Biological Activity of (Methoxyalkyl) thiazole and Methoxytetrahydropyran Hybrids. J. Med. Chem. 1994, 37, 512-518.
11. (b) Falgueyret, J.-P.; Denis, D.; Macdonald, D.; Hutchinson, J. H.; Riendeau, D. Characterization of the Arachidonate and ATP Binding Sites of Human 5-Lipoxygenase Using Photoaffinity Labeling and Enzyme Immobilization. Biochemistry 1995, 34, 13603-13611.
12. max of 14 μM at 2 h postdosage.
13. (a) Chauret, N.; Li, C.; Ducharme, Y.; Trimble, L. A.; Yergey, J. A.; Ramachandran, C.; Nicoll-Griffith, D. A. In Vitro and In Vivo Biotransformations of the Naphthalenic Lignan Lactone 5-Lipoxygenase Inhibitor, L-702,539. Drug. Metab. Dispos. 1995, 23, 65-71.
14. (b) Li, C.; Chauret, N.; Ducharme, Y.; Trimble, L. A.; Nicoll-Griffith, D. A.; Yergey, J. A. Integrated Application of Capillary HPLC/Continuous-Flow Liquid Secondary Ion Mass Spectrometry to Discovery Stage Metabolism Studies. Anal. Chem. 1995, 67, 2931-2936.
15. Fetizon, M.; Golfier, M.; Louis, J.-M. Oxydations par le carbonate d'argent sur celite-XIII. (Oxidation by silver carbonate on celite-XIII.) Tetrahedron 1975, 31, 171-176.
16. Danishefsky, S.; Webb, R. R., II. Lewis Acid Catalyzed Cyclocondensations of Formaldehyde with Activated Dienes. A Direct Route to Pyranosidal Pentoses. J. Org. Chem. 1984, 49, 1955-1958.
17. Smitherman, H. C.; Ferguson, L. N. On the Aromatic Character of 4-Pyrones. Tetrahedron 1968, 24, 923-932.
18. 1, a Stable Thromboxane A Analogue. J. Chem. Soc., Perkin Trans. I 1984, 1061-1068.
19. (a) Lefont, D.; Boullanger, P.; Cadas, O.; Descotes, G. A. Mild Procedure for the Preparation of 1,6-Anhydro-β-D-Hexopyranoses and Derivatives. Synthesis 1989, 191-194.
20. (b) Kelly, A. G.; Roberts, J. S. An Improved Synthesis of 1,6-Anhydro-2,4-dideoxy-β-D-threo-hexopyranose. Carbohydr. Res. 1979, 77, 231-233.
21. Shi-Qi, P.; Winterfeldt, E. Synthesis of Malonaldehyde Monoacetals. Liebigs Ann. Chem. 1989, 1045-1047.
22. Cywin, C. L.; Webster, F. X.; Kollmester, J. Synthesis of (-)-(6R,10R)-Matsuone. Assignment of Relative Stereochemistry to a Pheromone of Matsucoccus Pine Bast Scales. J. Org. Chem. 1991, 56, 2953-2955.
23. Bernardi, R.; Ghiringhelli, D. A. Short, Efficient Synthesis of (1S,3S,5R)- and(1S,3R,5R)-1,3-Dimethyl-2,9-dioxabicyclo[3.3.1]-nonane. J. Org. Chem. 1987, 52, 5021-5022.
24. Pelter, A.; Ward, R. S.; Pritchard, M. C.; Kay, I. T. Synthesis of Lignans Related to the Podophyllotoxin Series. J. Chem. Soc., Perkin Trans. I 1988, 1603-1613.
25. Therien, M.; Fitzsimmons, B. J.; Scheigetz, J.; Macdonald, D.; Choo, L. Y.; Guay, J.; Falgueyret, J. P.; Riendeau, D. Justicidin E: A New Leukotriene Biosynthesis Inhibitor. Biomed. Chem. Lett. 1993, 3, 2063-2066.
26. Heck, J. V.; Christensen, B. G. Nuclear Analogs of β-Lactam Antibiotics I. The Synthesis of 6β-Amidocyclonocardicins. Tetrahedron Lett. 1981, 22, 5027-5030.
27. Takano, S.; Otaki, S.; Ogasawara, K. A New Route to 1-Phenylnaphthalenes by Cycloaddition: A Simple and Selective Synthesis of some Naphthalene Lignan Lactones. Tetrahedron Lett. 1985, 26, 1659-1660.
28. El-Assal, L. S.; Shehab, A. H. β-Aroyl-α-arylmethylenepropionic Acids. Part II. The Synthesis and the Mechanism of Isomerisation of their Enol Lactones. J. Chem. Soc. 1961, 1658-1662.
29. Wood, J. L.; Khatri, N. A.; Weinreb, S. M. A Direct Conversion of Esters to Nitriles. Tetrahedron Lett. 1979, 20, 4907-4910.
30. Finnegan, R. A.; Bachman, P. L. Studies on Terpenes. IV. The Synthesis of a Bridged Tricyclic Ketone Embodying the BCD Ring System of Diterpenes of the Kaurene Class. J. Org. Chem. 1971, 36, 3196-3201.
31. Brideau, C.; Chan, C.; Charleson, S.; Denis, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Fortin, R.; Gillard, J. W.; Guay, D.; Guévremont, D.; Hutchinson, J. H.; Jones, T. R.; Léger, S.; Mancini, J. A.; McFarlane, C. S.; Pickett, C.; Piechuta, H.; Prasit, P.; Riendeau, D.; Rouzer, C. A.; Tagari, P.; Vickers, P. J.; Young, R. N.; Abraham, W. M. Pharmacology of MK-0591 (3-[1(4-Chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2- dimethyl propanoic acid), a Potent Orally Active Leukotriene Biosynthesis Inhibitor. Can J. Physiol. Pharmacol. 1992, 70, 799-807.
32. For a detailed conformational analysis of a related series of 5-LO inhibitors, see: Lambert-van der Brempt, C.; Bruneau, P.; Lamorlette, M. A. Conformational Analysis of 5-Lipoxygenase Inhibitors: Role of the Substituents in Chiral Recognition and on the Active Conformations of the (Methoxyalkyl)thiazole and Methoxytetrahydropyran Series. J. Med. Chem. 1994, 37, 113.
33. For a report on a related series of enantioselective 5-LO inhibitors, see: Crawley, G. C.; Briggs, M. T.; Dorvell, R. I.; Edwards, P. N.; Hamilton, P. M.; Kingston, J. F.; Oldham, K.; Waterson, D.; Whalley, D. P. 4-Methoxy-2-methyltetrahydropyrans: Chiral Leukotriene Biosynthesis Inhibitors, Related to ICI D2138, which Display Enantioselectivity. J. Med. Chem. 1993, 36, 295-296.
34. Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W. 5-Lipoxygenase Inhibitory Activity of Zileuton. J. Pharmacol. Exp. Ther. 1991, 256, 929-937.
35. Crawley, G. C.; Dowell, R. I.; Edwards, P. N.; Foster, S. J.; McMillan, R. M.; Walker, E. R. H.; Waterson, D. Methoxytetrahydropyrans. A New Series of Selective and Orally Potent 5-Lipoxygenase Inhibitors. J. Med. Chem. 1992, 35, 2600-2609.